股股交叉搭桥与血管内重建术治疗髂动脉闭塞的远期疗效:一项回顾性研究。

IF 3 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Edin Ahmic, Paul Swatek, Iurii Mykoliuk, Anton Busau, Muhammed Abdallah, Wolfgang Hitzl, Klaus Linni, Ara Ugurluoglu, Jörg Lindenmann
{"title":"股股交叉搭桥与血管内重建术治疗髂动脉闭塞的远期疗效:一项回顾性研究。","authors":"Edin Ahmic, Paul Swatek, Iurii Mykoliuk, Anton Busau, Muhammed Abdallah, Wolfgang Hitzl, Klaus Linni, Ara Ugurluoglu, Jörg Lindenmann","doi":"10.3390/jcm14062109","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective</b>: The objective of this study is to compare the long-term outcomes of femorofemoral crossover bypass (FCOB) and endovascular treatment (ET) in managing iliac artery occlusions. <b>Methods</b>: The data of 200 patients with iliac artery lesions who were treated at a single center within 7 years were evaluated retrospectively. Of these, 82 (41%) underwent FCOB, and 118 (59%) received ET. Primary outcomes included patency, limb salvage, and survival rates, while secondary outcomes assessed complications, including wound infections and restenosis. Follow-up was conducted over a median of 4.98 years. <b>Results</b>: Primary patency (PP) rates after 3 years were 80% for FCOB and 88% for ET. Primary assisted patency (PAP) was 95% for FCOB and 93% for ET. Secondary patency (SP) was 97% for FCOB and 98% for ET. Both FCOB and ET achieved comparable long-term outcomes in limb salvage, 94% in both groups at 8 years. ET demonstrated advantages in shorter hospital stays (1.49 ± 2.51 vs. 8.21 ± 9.82 days, <i>p</i> < 0.0001) and lower perioperative complications, including transfusion rates (3.4% vs. 13.4%, <i>p</i> = 0.01226). However, FCOB exhibited lower restenosis rates (6.1% vs. 20.39%, <i>p</i> = 0.00441), despite a higher rate of reocclusion (19.5% vs. 6.8%, <i>p</i> = 0.00800). Survival rates at 8 years were 54% for FCOB and 67% for ET. <b>Conclusions</b>: ET is the preferred first-line approach due to its minimally invasive technique, shorter recovery time, and fewer complications. FCOB remains essential for patients with complex lesions or when ET is not feasible, offering durable long-term outcomes. Appropriate treatment selection should consider both the patient's condition and clinical and anatomical factors to optimize the best possible patient outcomes.</p>","PeriodicalId":15533,"journal":{"name":"Journal of Clinical Medicine","volume":"14 6","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11943187/pdf/","citationCount":"0","resultStr":"{\"title\":\"Long-Term Outcomes of Femorofemoral Crossover Bypass Versus Endovascular Revascularization in Iliac Artery Occlusions: A Retrospective Study.\",\"authors\":\"Edin Ahmic, Paul Swatek, Iurii Mykoliuk, Anton Busau, Muhammed Abdallah, Wolfgang Hitzl, Klaus Linni, Ara Ugurluoglu, Jörg Lindenmann\",\"doi\":\"10.3390/jcm14062109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective</b>: The objective of this study is to compare the long-term outcomes of femorofemoral crossover bypass (FCOB) and endovascular treatment (ET) in managing iliac artery occlusions. <b>Methods</b>: The data of 200 patients with iliac artery lesions who were treated at a single center within 7 years were evaluated retrospectively. Of these, 82 (41%) underwent FCOB, and 118 (59%) received ET. Primary outcomes included patency, limb salvage, and survival rates, while secondary outcomes assessed complications, including wound infections and restenosis. Follow-up was conducted over a median of 4.98 years. <b>Results</b>: Primary patency (PP) rates after 3 years were 80% for FCOB and 88% for ET. Primary assisted patency (PAP) was 95% for FCOB and 93% for ET. Secondary patency (SP) was 97% for FCOB and 98% for ET. Both FCOB and ET achieved comparable long-term outcomes in limb salvage, 94% in both groups at 8 years. ET demonstrated advantages in shorter hospital stays (1.49 ± 2.51 vs. 8.21 ± 9.82 days, <i>p</i> < 0.0001) and lower perioperative complications, including transfusion rates (3.4% vs. 13.4%, <i>p</i> = 0.01226). However, FCOB exhibited lower restenosis rates (6.1% vs. 20.39%, <i>p</i> = 0.00441), despite a higher rate of reocclusion (19.5% vs. 6.8%, <i>p</i> = 0.00800). Survival rates at 8 years were 54% for FCOB and 67% for ET. <b>Conclusions</b>: ET is the preferred first-line approach due to its minimally invasive technique, shorter recovery time, and fewer complications. FCOB remains essential for patients with complex lesions or when ET is not feasible, offering durable long-term outcomes. Appropriate treatment selection should consider both the patient's condition and clinical and anatomical factors to optimize the best possible patient outcomes.</p>\",\"PeriodicalId\":15533,\"journal\":{\"name\":\"Journal of Clinical Medicine\",\"volume\":\"14 6\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-03-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11943187/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jcm14062109\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jcm14062109","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究的目的是比较股股交叉搭桥(FCOB)和血管内治疗(ET)治疗髂动脉闭塞的长期疗效。方法:回顾性分析7年来在单中心治疗的200例髂动脉病变患者的资料。其中,82例(41%)接受了FCOB, 118例(59%)接受了ET。主要结局包括通畅、肢体保留和生存率,而次要结局评估并发症,包括伤口感染和再狭窄。随访时间中位数为4.98年。结果:3年后,FCOB的原发性通畅率为80%,ET为88%。FCOB的原发性辅助通畅率为95%,ET为93%。FCOB的继发通畅率为97%,ET为98%。FCOB和ET在肢体保留方面的长期疗效相当,8年时两组均为94%。ET在缩短住院时间(1.49±2.51天对8.21±9.82天,p < 0.0001)和降低围手术期并发症(包括输血率3.4%对13.4%,p = 0.01226)方面具有优势。然而,FCOB的再狭窄率较低(6.1%比20.39%,p = 0.00441),尽管再闭塞率较高(19.5%比6.8%,p = 0.00800)。FCOB的8年生存率为54%,ET的8年生存率为67%。结论:ET因其微创技术、恢复时间短、并发症少而成为首选的一线入路。FCOB对于复杂病变或ET不可行的患者仍然是必不可少的,提供持久的长期结果。适当的治疗选择应考虑患者的病情和临床及解剖学因素,以优化患者的最佳可能结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Long-Term Outcomes of Femorofemoral Crossover Bypass Versus Endovascular Revascularization in Iliac Artery Occlusions: A Retrospective Study.

Objective: The objective of this study is to compare the long-term outcomes of femorofemoral crossover bypass (FCOB) and endovascular treatment (ET) in managing iliac artery occlusions. Methods: The data of 200 patients with iliac artery lesions who were treated at a single center within 7 years were evaluated retrospectively. Of these, 82 (41%) underwent FCOB, and 118 (59%) received ET. Primary outcomes included patency, limb salvage, and survival rates, while secondary outcomes assessed complications, including wound infections and restenosis. Follow-up was conducted over a median of 4.98 years. Results: Primary patency (PP) rates after 3 years were 80% for FCOB and 88% for ET. Primary assisted patency (PAP) was 95% for FCOB and 93% for ET. Secondary patency (SP) was 97% for FCOB and 98% for ET. Both FCOB and ET achieved comparable long-term outcomes in limb salvage, 94% in both groups at 8 years. ET demonstrated advantages in shorter hospital stays (1.49 ± 2.51 vs. 8.21 ± 9.82 days, p < 0.0001) and lower perioperative complications, including transfusion rates (3.4% vs. 13.4%, p = 0.01226). However, FCOB exhibited lower restenosis rates (6.1% vs. 20.39%, p = 0.00441), despite a higher rate of reocclusion (19.5% vs. 6.8%, p = 0.00800). Survival rates at 8 years were 54% for FCOB and 67% for ET. Conclusions: ET is the preferred first-line approach due to its minimally invasive technique, shorter recovery time, and fewer complications. FCOB remains essential for patients with complex lesions or when ET is not feasible, offering durable long-term outcomes. Appropriate treatment selection should consider both the patient's condition and clinical and anatomical factors to optimize the best possible patient outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Clinical Medicine
Journal of Clinical Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
5.70
自引率
7.70%
发文量
6468
审稿时长
16.32 days
期刊介绍: Journal of Clinical Medicine (ISSN 2077-0383), is an international scientific open access journal, providing a platform for advances in health care/clinical practices, the study of direct observation of patients and general medical research. This multi-disciplinary journal is aimed at a wide audience of medical researchers and healthcare professionals. Unique features of this journal: manuscripts regarding original research and ideas will be particularly welcomed.JCM also accepts reviews, communications, and short notes. There is no limit to publication length: our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信